# Pizarra — PT-pseudo_2e0346bce3b3 (task 1)

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_2e0346bce3b3
Task: 1

Encounter: Urology - outpatient on 22 Jan 2025.
Referrer: Dr. M. Jansen (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 64-year-old male
  - PSA: 3.5 ng/mL
  - mpMRI — PI-RADS score: 4 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.01 ng/mL²
  - PSA velocity: 0.63 ng/mL/yr
  - Prior PSA: 3.1 ng/mL
  - Prostate volume: 99.0 mL
  - Months since last PSA: 2
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.7092595 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: COPD
  - Problem list / PMHx: COPD
  - Current medication: salbutamol PRN
  - Allergies: NKA
  - Additional notes: PSA 3.5 ng/mL. PI-RADS 4. PSAD 0.01. Prostate volume 99 mL. csPCa 0.71.

Vitals: weight 68 kg, height 183 cm, BMI 20.3, BP 137/71 mmHg, HR 70 bpm. Smoking: Ex-smoker (31 pack-yr, quit 2021).

Chief complaint: Assessment driven by a previously positive prostate biopsy and a steady upward trajectory in PSA measurements.

History: A 64-year-old delivery driver initially sought evaluation for elevated PSA levels in mid-2022, leading to a biopsy that confirmed low-grade disease. Following a divorce, he resides independently, with his adult daughter serving as his main point of contact. He experiences mild lower urinary tract symptoms, scoring a 6 on the IPSS scale, and manages these without alpha-blocker therapy. A smoking history of 31 pack-years was recorded before he ceased tobacco use in 2021; COPD remains stable, requiring only PRN salbutamol. He engages in light weight-training twice weekly at home and abstains from alcohol. Recent endocrinology consultations centered on routine thyroid screening, and he reports a right knee meniscectomy performed in his early twenties that remains stable without current functional limitations. There is no report of bone pain, haematuria, or unexplained weight loss.

Physical examination: Normal DRE: The prostate presents as symmetrically enlarged yet smooth, lacking any palpable nodules or asymmetry. General assessment shows no abnormalities; height measures 183 cm, weight 68 kg, yielding a BMI of 20.3. Vital signs record a blood pressure of 137/71 mmHg and a heart rate of 70 bpm. Bilateral lung fields are clear, and the cardiovascular examination falls within normal limits.

Patient info: delivery driver; Divorced; Lives alone; adult daughter is primary contact.
Next of kin: None recorded — patient declines to nominate.

Lifestyle: alcohol 0 units / week (alcohol-free); exercise Light weight-training at home, 2x/week; IPSS score: 6/35 (mild LUTS).

Recent other appointments: Endocrine — thyroid screening.
Admin: Interpreter: not required. Consent for data use: signed.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents actually exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status shown in the panel above is all the pathology information on record.]

## [2] INITIAL RECOMMENDATION (statistical prior)

**EXPERT-PRIOR** — *statistical expert; k-NN over 8 structured variables of THIS prompt only, trained on 91 labelled cases, leave-one-out honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: NO BIOPSY
  p(biopsy = yes) = 0.47 +/- 0.19   (95% CI 0.12-0.84)

Where the uncertainty comes from:
  - aleatoric  dA = 0.16  (the nearest labelled cases disagree with each other)
  - epistemic  dA = 0.11  (few labelled cases resemble this one)
  - 6.5 effective neighbours out of 10; 2 of the 5 closest labelled cases were biopsied
  - 80%-coverage conformal set: {no}

TIER 'discuss': A +/- dA straddles 0.5. The classifier genuinely CANNOT tell these two answers apart; measured accuracy in this tier is 0.61, barely above the 0.62 majority-class rate. Its number is a starting point only, and the case must be decided on the clinical evidence retrieved by the other participants.

Variables it actually read (from the visible panel only, no documents retrieved):
  pirads=4.0, bx_ord=3.0, psa=3.5, age=64.0, psad=0.01, dre_ord=0.0, vol=99.0, n_pmhx=1.0
  missing / not evaluable: none

Out-of-fold performance of this recommender on the 91 labelled cases (5x5 CV):
  accuracy 0.703, balanced accuracy 0.662, AUC 0.75, ECE 0.095.
It is right about 7 times out of 10 overall. It is NOT an oracle and it has never seen the
radiology report, the PSA trajectory, the laboratory panel or the previous notes.

## [3] GAPS AND DOUBTS

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
  The statistical recommender only used the structured panel. It could not weigh the patient's PSA velocity (0.63 ng/mL/yr) against the prior PSA (3.1 ng/mL) and the PI-RADS 4 score. It also could not incorporate the specific findings from the mpMRI report or the full laboratory panel, which are crucial for assessing the true extent of the lesion and overall health context.

WHY THE SUGGESTION COULD BE WRONG
  The prior suggests 'NO BIOPSY' with a wide interval (0.47 +/- 0.19), indicating high uncertainty. A failure mode is that the prior ignores the rising PSA trend (PSA 3.1 to 3.5 over 2 months) which might push the probability towards 'YES'. Another failure mode is that the prior does not account for the prior positive biopsy status, which might suggest a need for surveillance rather than immediate re-biopsy, despite the current PI-RADS 4.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
  <document> radiology / mpMRI report -> If the report details high-risk features or extent, it would increase the need for further action.
  <document> PSA history (trend) -> If the velocity is significantly high, it would increase the need for further action.
  <document> previous GP / urology consultation notes -> These notes might clarify the clinical context or the rationale for the prior positive biopsy.
  <document> laboratory results (full panel) -> This could reveal other markers that influence the risk stratification.

## [4] EVIDENCE REPORT

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
  One block per document you opened. Quote the values and phrases that matter, verbatim and with units. Numbers, lesion descriptions, dates, explicit radiologist or clinician recommendations. Do not paraphrase a number. If a document turned out to be uninformative, say so in one line - that is an honest result.
  
  **radiology / mpMRI report**
  {"case_id": "PT-pseudo_2e0346bce3b3", "radiology_report": "Subject: mpMRI Prostate | Date: 20 Jan 2025 | Institution: Amsterdam UMC (AMC)\n\nClinical Context: Assessment of a PSA value of 3.5 ng/mL alongside a previously positive biopsy.\n\nFINDINGS:\nProstatic volume registers at 99.0 mL. T2-weighted sequences highlight a focal hypointense area within the left posterior peripheral zone at the base, spanning roughly 18 mm. DWI shows pronounced restriction with a matching low-signal ADC map. DCE sequences demonstrate early, focal enhancement compared to adjacent tissue. Bilateral neurovascular bundles remain intact. Seminal vesicle invasion is absent. The bladder and pelvic lymph nodes appear normal.\n\nIMPRESSION:\nPI-RADS 4 lesion located in the left posterior peripheral zone, measuring approximately 18 mm. Prostate volume 99.0 mL yielding a PSA density of 0.01 ng/mL/mL. csPCa predicted probability 0.7092595."}
  
  **psa_trend**
  {"case_id": "PT-pseudo_2e0346bce3b3", "psa_trend": [{"date": "Jun 2022", "val": 1.9}, {"date": "Apr 2023", "val": 2.3}, {"date": "Mar 2024", "val": 2.9}, {"date": "Jan 2025", "val": 3.5}]}
  
  **previous_notes**
  {"case_id": "PT-pseudo_2e0346bce3b3", "previous_notes": [{"date": "24 Sep 2024", "author": "Dr. M. Jansen (GP)", "text": "During a clinical review on 24 September 2024, a PSA increase to 3.1 ng/mL recorded in March was noted alongside a history of a previously positive biopsy. Routine laboratory panels returned within normal limits, and the patient continues to utilize salbutamol on an as-needed basis for COPD management."}]}
  
  **laboratory_results**
  {"case_id": "PT-pseudo_2e0346bce3b3", "laboratory_results": [{"name": "PSA", "val": "3.5 ng/mL", "date": "26 Dec 2024", "flag": ""}, {"name": "Free PSA", "val": "0.91 ng/mL", "date": "26 Dec 2024", "flag": ""}, {"name": "%Free PSA", "val": "26%", "date": "26 Dec 2024", "flag": ""}, {"name": "Haemoglobin", "val": "14.8 g/dL", "date": "26 Dec 2024", "flag": ""}, {"name": "WBC", "val": "9.4 x10^9/L", "date": "26 Dec 2024", "flag": ""}, {"name": "Platelets", "val": "153 x10^9/L", "date": "26 Dec 2024", "flag": ""}, {"name": "Creatinine", "val": "90 umol/L", "date": "26 Dec 2024", "flag": ""}, {"name": "eGFR", "val": ">60 mL/min/1.73m2", "date": "26 Dec 2024", "flag": ""}, {"name": "Testosterone", "val": "20.4 nmol/L", "date": "26 Dec 2024", "flag": ""}, {"name": "Alkaline phosphatase", "val": "95 U/L", "date": "26 Dec 2024", "flag": ""}, {"name": "LDH", "val": "161 U/L", "date": "26 Dec 2024", "flag": ""}]}

NOT RETRIEVED
  get_family_history - Do NOT call this. In this reading form the family-history anamnesis is not part of the biopsy work-up, and a positive or negative first-degree history does not change whether this patient is sampled today.

WHAT THE EVIDENCE SUPPORTS
  FOR sampling this patient now:
  - PI-RADS 4 lesion located in the left posterior peripheral zone, measuring approximately 18 mm.
  - PSA velocity of 0.63 ng/mL/yr, indicating a rising trend from 3.1 ng/mL to 3.5 ng/mL over 2 months.
  - csPCa predicted probability of 0.7092595.
  
  AGAINST sampling this patient now:
  - Prior biopsy was positive.
  - Previous notes indicate routine lab panels returned within normal limits at the time of the last review.

WHERE THIS LEANS
  The retrieved evidence strongly supports further investigation due to the PI-RADS 4 finding and the rising PSA velocity, which contradicts the statistical prior suggesting no biopsy.

[Sections actually revealed in this consultation: radiology_report, psa_trend, previous_notes, laboratory_results. Tools executed: get_lab_results, get_mri_report, get_previous_notes, get_psa_trend.]

## [5] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [6] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: clear)

A biopsy is recommended because the evidence strongly supports further investigation due to the PI-RADS 4 lesion measuring 18 mm and a rising PSA velocity of 0.63 ng/mL/yr. This finding is important, as it contradicts the statistical prior suggesting no biopsy. The decision is driven by the PI-RADS 4 score and the rising PSA trend from 3.1 ng/mL to 3.5 ng/mL over two months, despite the prior positive biopsy.

Variables that carried weight: bx=decisive, psa=important, vol=noted, psad=noted, pirads=decisive
Sections revealed: radiology_report, psa_trend, previous_notes, laboratory_results
